Seeking Alpha

AVITA Medical: Financial Challenges Ahead, Despite Innovative RECELL Device

AVITA Medical specializes in regenerative medicine and has an innovative device for skin restoration that treats full-thickness skin defects and vitiligo. The RECELL device uses a patient's skin cells ...
Seeking Alpha

AVITA Medical Achieves Milestone with First Case Using RECELL GO

VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound ...
Nasdaq

AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe

VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced ...
Healio

Melanocyte keratinocyte transplantation offers promising procedural option for vitiligo

Please provide your email address to receive an email when new articles are posted on . Melanocyte keratinocyte transplantation can yield significant repigmentation ranging from 70% to 100%. The ...
Morningstar

Avita’s Road to Profitability Is Long, but It Continues to Take the Right Steps

We expect Avita’s RECELL to pose a significant challenge to the standard of care for larger burns, currently a skin graft sourced from elsewhere on the patient’s body. We believe Avita will be ...
Los Angeles Business Journal

Avita Gets FDA Nod For Device

The Food and Drug Administration signs off on a new wound treatment device by Avita Medical. Tech: Avita's Recell. Valencia-based Avita Medical Inc. has received FDA approval for a version of its ...
Eagle-Tribune

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
Morningstar

AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

RECELL GO retains these clinical benefits while enhancing procedural consistency and surgical team coordination, with the physician remaining central throughout the procedure. This design supports ...
Nasdaq

Avita Medical lowers Q4 revenue view to ~$18.4M from $22.3M-$24.3M

Q4 consensus $35.85M. For the quarter ended December 31, 2024, AVITA Medical (RCEL) now expects commercial revenue to be approximately $18.4M, reflecting growth of around 30% over the same period in ...
Business Wire

First Patient Enrolled in AVITA Therapeutic’s Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform ...